Hangzhou, China – Nov. 6, 2026 – Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190) and GL Capital announced a cash investment in LifeTech Scientific Corporation (HKEX: 1302).
The funding will be used to create a combined platform for vascular and structural heart procedures in China. Both parties said the partnership will bring together manufacturing capacity and clinical expertise to speed product development.
Building a joint vascular and structural heart platform
Zylox-Tonbridge and GL Capital are providing capital to LifeTech to expand its product pipeline. The goal is to design a single platform that supports a range of heart-related interventions, from stents to valve replacements. LifeTech contributes its established production facilities, while Zylox-Tonbridge adds its clinical knowledge and device designs. By sharing resources, the companies expect to shorten the time needed to move a device from concept to market.
Integrating existing vascular solutions with new technology
The new platform will incorporate Zylox-Tonbridge’s current portfolio of vascular tools. Recent work in wire technologies and surgical robotics will be added to LifeTech’s manufacturing line. This integration creates a more unified set of products for hospitals, reducing the need to work with multiple suppliers. Clinicians will have access to tools that work together smoothly, which should improve procedural efficiency and patient safety.
Growth outlook for structural heart interventions
The structural heart market is expanding rapidly worldwide. Patients and doctors are choosing less invasive treatments that allow quicker recovery. According to TrendX Insights’ Structural Heart Market, the sector is expected to reach US$43.2 billion by 2034, growing at a 14.8% compound annual rate. The investment by Zylox-Tonbridge and LifeTech positions them to capture a share of this rising demand.
Implications for investors and market partners
The infusion of capital strengthens Zylox-Tonbridge’s foothold in the medical-device arena and adds a new revenue stream beyond its existing products. GL Capital’s participation brings additional financial stability and strategic oversight. For LifeTech, the partnership opens doors to advanced technology and new customer segments.
Together, the firms anticipate smoother regulatory pathways and shared research costs, which should improve profitability for both sides. Suppliers and distributors can expect a more reliable partner with broader product offerings.
For further details on corporate developments, visit the Press Release Archives.